US · Healthcare · Biotechnology
EPS came in at -0.03 against a street estimate of -0.06 — a beat of 50.0%.
Analysts rate Lexicon Pharmaceuticals Inc a buy (4 buy, 2 hold, 0 sell out of 6) with an average price target of $4.46.
| Fund | Stake |
|---|---|
| Artal Group S A | 39.43% |
| FMR Inc | 11.66% |
| Siren, L.L.C. | 9.97% |
| Sessa Capital, L.P | 4.27% |
| BlackRock Inc | 3.91% |
| Vanguard Capital Management, LLC | 2.23% |
| Point72 Asset Management, L.P. | 1.86% |
| Geode Capital Management, LLC | 1.41% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $11,250,000, down from $14,182,000 in the third quarter of 2025. • Nine-month 2026 revenue was $33 | 2026-11-05 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $11.3 million, down from $14.2 million in the third quarter of 2025. • Net loss was $14.0 million, | 2026-11-05 |
| Quarterly report · Q2 2026 LEXICON PHARMACEUTICALS, INC. - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash Position: $40.9 million in cash and equivalents plus $149.7 million in | 2026-08-06 |
| Results announced · Q3 2026 LEXICON PHARMACEUTICALS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 Total Revenues: $0.7 million (vs. $28.9 million in Q2 2025) • Q2 2026 N | 2026-08-06 |
| Quarterly report · Q1 2026 LEXICON PHARMACEUTICALS, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash & Investments: $199.7 million in total liquidity (cash $38.1M, short-te | 2026-05-07 |
| Results announced · Q2 2026 LEXICON PHARMACEUTICALS Q1 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Total revenues: $21.1 million (Q1 2026) vs $1.3 million (Q1 2025) - Licensing | 2026-05-07 |
| Material agreement · Q2 2026 LEXICON PHARMACEUTICALS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • $100 million total borrowing capacity from Hercules Capital in loan and security | 2026-05-06 |
| Material agreement · Q2 2026 LEXICON PHARMACEUTICALS, INC. – FORM 8-K SUMMARY As of April 30, 2026 --- HEADLINE NUMBERS • 408,434.7 shares of Series B Convertible Preferred Sto | 2026-04-30 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Lexicon Pharmaceuticals Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.